SiteOne Therapeutics, Inc. raised $100 million in a Series C financing led by Novo Holdings to advance selective ion channel modulators for non-opioid treatments of pain.

Dec 18, 2024•about 1 year ago

Amount Raised

$100 Million

Round Type

series c

San FranciscoBiotechnologyHealthcare

Investors

Bsquared CapitalMission Bio CapitalWellington ManagementOrbi MedNovo Holdings

Description

SiteOne Therapeutics, Inc. announced a $100 million Series C financing led by Novo Holdings with participation from several investors. The financing will support the development of their portfolio focused on treating sensory hyperexcitability disorders. SiteOne is dedicated to creating non-opioid treatments, and this funding will enable human clinical proof of concept studies.

Company Information

Company

SiteOne Therapeutics

Location

280 Utah Ave., Suite 250

San Francisco, California, United States

About

SiteOne Therapeutics, Inc. is a biopharmaceutical company developing selective ion channel modulators aimed at treating conditions such as pain and cough. The company's focus is on creating non-opioid treatments that target sensory hyperexcitability disorders. Their lead program targets the NaV1.8 channel, with a focus on providing effective analgesia while minimizing side effects and abuse potential. SiteOne's innovative approach prioritizes the development of therapeutics that directly affect the peripheral nervous system.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends